

# 5<sup>th</sup> International Conference on Vaccines, Immunology and Clinical Trials

## March 23-24, 2022 | Webinar

Volume: 12

### Early proof of concept with human viral challenge models in vaccine development

**Clayton A Dehn**

High Point Clinical Trials, USA

The pharmaceutical industry is constantly searching for efficiencies for the development of new medicinal products. Viral vaccine development is no exception. The [Human Viral Challenge Model](#) (HVCM) is a widely accepted alternative to field studies. The standardized exposure of intentional [viral inoculation](#) of volunteers in a controlled clinical environment enriches the prevalence of infection. This also permits the study of the entire disease lifecycle from health to disease and recovery back to health. These methods reduce study population size requirements and the overall trial duration. The [cumulative effect](#) of these advantages is a risk and cost containing accelerated route to market for antiviral drugs, diagnostics and vaccines.

#### Biography

Clayton Dehn is a clinical research physiologist with particular expertise in Proof-of-Concept testing methods. He is a co-inventor of a process and substance for disturbing the inheritance pattern of ion-channelopathic disorders by selectively disabling genetically undesirable sperm cells. He is also the sole author of the first publication cautioning against the risk of SGLT-inhibition inducing ketoacidosis in insulinopenic populations. Clayton brings over 15 years of knowledge and international experience as a clinical research professional in the drug development industry.

[cdehn@highpointctc.com](mailto:cdehn@highpointctc.com)